吉非替尼治疗晚期非小细胞肺癌临床观察

Clinical experience of gefitinib in treatment of advanced non-small cell lung cancer

目的评价吉非替尼单药治疗晚期化疗后进展的非小细胞肺癌的疗效和不良反应。方法108例经病理确诊既往化疗失败的晚期非小细胞肺癌患者,吉非替尼250 mg口服,每日1次,连续用药至肿瘤进展或发生不可耐受的不良反应。结果106例可评价,总有效率22.6%。女性的有效率高于男性(P=0.018),腺癌的有效率高于非腺癌(P=0.040),不吸烟者的有效率高于吸烟者(P=0.019)。疾病控制率73.6%,中位无进展生存期为5个月,中位生存期为9个月。不良反应主要是Ⅰ、Ⅱ度皮疹和腹泻。结论吉非替尼治疗既往化疗失败的晚期非小细胞肺癌,具有较好的疗效和安全性。

Objective To evaluate the safety and efficacy of gefitinib treatment for patients with locally advanced or metastatic non-small cell lung cancer （NSCLC） after previous chemotherapy. Methods A total of 108 pathologically-confirmed NSCLC patients after previous chemotherapy were enrolled. Gefitinib was orally administered 250 mg once daily until disease progression or the occurrence of intolerable toxicity. Results One hundred and six such patients were evaluable for response and toxicity assessment. The objective response rate was 22.6%, The disease control rate was 73.6%. The objective response rate in female was significantly higher than that in male （P=0. 018）. The objective response rate in adenocarcinoma was significantly higher than that in Non-adenocarcinoma carcinoma （P=0. 040）. The objective response rate in smoker was significantly higher than that in Non-smoker （P=0. 019）. The median progression-free survival time was five months. The median overall survival time was nine months. The most common drug-related adverse events were grade I or II rash and diarrhea. Conclusion Gefitinib is effective and safe in treating patientswith locally advanced or metastatic NSCLC after failure of previous chemotherapy.